Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
- Status
- COMPLETED
- Phase
- PHASE2
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
- Status
- COMPLETED
- Phase
- PHASE1
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
- Status
- COMPLETED
- Phase
- NA
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
- Status
- COMPLETED
- Phase
- NA
Freiburg ZNS-NHL Study
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
- Status
- COMPLETED
- Phase
- PHASE2